» Articles » PMID: 25255101

Cathepsin B in Antigen-presenting Cells Controls Mediators of the Th1 Immune Response During Leishmania Major Infection

Overview
Date 2014 Sep 26
PMID 25255101
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Resistance and susceptibility to Leishmania major infection in the murine model is determined by the capacity of the host to mount either a protective Th1 response or a Th2 response associated with disease progression. Previous reports involving the use of cysteine cathepsin inhibitors indicated that cathepsins B (Ctsb) and L (Ctsl) play important roles in Th1/Th2 polarization during L. major infection in both susceptible and resistant mouse strains. Although it was hypothesized that these effects are a consequence of differential patterns of antigen processing, the mechanisms underlying these differences were not further investigated. Given the pivotal roles that dendritic cells and macrophages play during Leishmania infection, we generated bone-marrow derived dendritic cells (BMDC) and macrophages (BMM) from Ctsb-/- and Ctsl-/- mice, and studied the effects of Ctsb and Ctsl deficiency on the survival of L. major in infected cells. Furthermore, the signals used by dendritic cells to instruct Th cell polarization were addressed: the expression of MHC class II and co-stimulatory molecules, and cytokine production. We found that Ctsb-/- BMDC express higher levels of MHC class II molecules than wild-type (WT) and Ctsl-/- BMDC, while there were no significant differences in the expression of co-stimulatory molecules between cathepsin-deficient and WT cells. Moreover, both BMDC and BMM from Ctsb-/- mice significantly up-regulated the levels of interleukin 12 (IL-12) expression, a key Th1-inducing cytokine. These findings indicate that Ctsb-/- BMDC display more pro-Th1 properties than their WT and Ctsl-/- counterparts, and therefore suggest that Ctsb down-regulates the Th1 response to L. major. Moreover, they propose a novel role for Ctsb as a regulator of cytokine expression.

Citing Articles

Dual viscosity mixture vehicle for intratympanic steroid treatment modifies the ROS and inflammation related proteomes.

Jung J, Li H, Lee J, Hwang Y, Dan K, Park M Front Pharmacol. 2023; 14:1081724.

PMID: 36744248 PMC: 9892634. DOI: 10.3389/fphar.2023.1081724.


Single-cell analyses reveal early thymic progenitors and pre-B cells in zebrafish.

Rubin S, Baron C, Pessoa Rodrigues C, Duran M, Corbin A, Yang S J Exp Med. 2022; 219(9).

PMID: 35938989 PMC: 9365674. DOI: 10.1084/jem.20220038.


The aging immune system in Alzheimer's and Parkinson's diseases.

Heavener K, Bradshaw E Semin Immunopathol. 2022; 44(5):649-657.

PMID: 35505128 PMC: 9519729. DOI: 10.1007/s00281-022-00944-6.


The Mycotoxin Beauvericin Exhibits Immunostimulatory Effects on Dendritic Cells Activating the TLR4 Signaling Pathway.

Yang X, Ali S, Zhao M, Richter L, Schafer V, Schliehe-Diecks J Front Immunol. 2022; 13:856230.

PMID: 35464417 PMC: 9024221. DOI: 10.3389/fimmu.2022.856230.


CTSB is a negative prognostic biomarker and therapeutic target associated with immune cells infiltration and immunosuppression in gliomas.

Ma K, Chen X, Liu W, Chen S, Yang C, Yang J Sci Rep. 2022; 12(1):4295.

PMID: 35277559 PMC: 8917123. DOI: 10.1038/s41598-022-08346-2.


References
1.
Riese R, Wolf P, Bromme D, Natkin L, Villadangos J, Ploegh H . Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity. 1996; 4(4):357-66. DOI: 10.1016/s1074-7613(00)80249-6. View

2.
Matsumoto F, Saitoh S, Fukui R, Kobayashi T, Tanimura N, Konno K . Cathepsins are required for Toll-like receptor 9 responses. Biochem Biophys Res Commun. 2008; 367(3):693-9. DOI: 10.1016/j.bbrc.2007.12.130. View

3.
Maekawa Y, Himeno K, Ishikawa H, Hisaeda H, Sakai T, Dainichi T . Switch of CD4+ T cell differentiation from Th2 to Th1 by treatment with cathepsin B inhibitor in experimental leishmaniasis. J Immunol. 1998; 161(5):2120-7. View

4.
Ponte-Sucre A, Vicik R, Schultheis M, Schirmeister T, Moll H . Aziridine-2,3-dicarboxylates, peptidomimetic cysteine protease inhibitors with antileishmanial activity. Antimicrob Agents Chemother. 2006; 50(7):2439-47. PMC: 1489792. DOI: 10.1128/AAC.01430-05. View

5.
Mattner F, Magram J, Ferrante J, Launois P, Di Padova K, BEHIN R . Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol. 1996; 26(7):1553-9. DOI: 10.1002/eji.1830260722. View